Spanish customized adjuvant trial (SCAT) based on BRCA1 mRNA levels

Predictive markers in the adjuvant therapy of non-small cell lung cancer

“…To further study the role of BRCA1 as a biomarker, the Spanish Customized Adjuvant Treatment (SCAT) trial evaluated adjuvant chemotherapy based on BRCA1 levels in patients with completely resected stage II and III NSCLC [32]. Patients received cisplatin plus gemcitabine (low BRCA1 expression), cisplatin plus docetaxel (intermediate BRCA1 expression), or docetaxel (high BRCA1 expression).…”

Systemic and Targeted Therapies for Early-Stage Lung Cancer

“…The Spanish Lung Cancer Group recently reported their feasibility study utilizing BRCA mRNA expression to determine adjuvant therapy in patients with resected stage II-III NSCLC. 34 Assignment of patients to customized chemotherapy was shown to be feasible, with no detrimental effect of treating patients with high BRCA1 levels with docetaxel alone. A randomized phase III trial utilizing the same design, the Spanish Customized Adjuvant Trial (SCAT), is ongoing.…”

Biomarkers with Predictive and Prognostic Function in Non–Small Cell Lung Cancer: Ready for Prime Time?

“…27 The phase III Spanish Customized Adjuvant Treatment (SCAT) trial is based on data showing that low BRCA1 mRNA levels predict for longer survival with cisplatin-based chemotherapy, whereas high BRCA1 levels predict for resistance to cisplatin and therefore should be treated with a taxane-based regimen instead. 28,29 In a recently reported feasibility study, adjuvant chemotherapy was customized based on BRCA1 mRNA levels in 84 patients with completely resected NSCLC. 30 Patients received docetaxel for high levels of BRCA1, docetaxel/cispl-mous cell carcinomas suggest that pemetrexed may be a more effective drug for nonsquamous NSCLCs.…”